Enliven Therapeutics, Inc. (ELVN)

24.00 +0.96 (+4.17%) At close: 04:00PM EDT

Enliven Therapeutics, Inc.

6200 Lookout Road
Boulder, CO 80301
United States
720 647 8519
https://www.enliventherapeutics.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 50

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Samuel S. Kintz M.B.A.	Co-Founder, CEO, Secretary & Director	866.41k	N/A	1986
Dr. Joseph P. Lyssikatos Ph.D.	Co-Founder, Chief Scientific Officer & Directors	632.67k	N/A	1965
Dr. Helen Louise Collins M.D.	Chief Medical Officer	686.19k	N/A	1963
Mr. Anish Patel Pharm.D.	Co-Founder & COO	N/A	N/A	1981
Mr. Benjamin Hohl	CFO & Head of Corporate Development	488.5k	N/A	1990
Dr. Galya D. Blachman Esq., Ph.D.	Chief Legal Officer & Head of Business Development	N/A	N/A	1977

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.

Corporate Governance

Enliven Therapeutics, Inc.’s ISS Governance QualityScore as of May 1, 2024 is 6. The pillar scores are Audit: 5; Board: 4; Shareholder Rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.